Table 3.

Graft outcomes in those with atypical hemolytic uremic syndrome with and without prophylactic eculizumab treatment

Graft outcome	Control cohort (n = 33)	Prophylactic eculizumab cohort (n = 38)
Functioning (%)	11 (33.3)***	31 (81.6)
Failed (%)	22 (66.7)***	7 (18)
Cause of graft failure (% of transplants)
Posttransplant TMA	14 (42.4)***	1 (2.6)
Rejection	5 (15.2)	4 (10.5)
Other	3 (9.1): graft thrombosis, nonviable infarcted kidney with primary nonfunction, transplant glomerulopathy	2 (5.3): meningococcal sepsis, immune complex mediated glomerulonephritis
Recipient death with functioning graft (% of those with functioning graft)	0	5 (16.1)
Median (range) follow-up time for those alive with functioning graft	7.9 y (2.0-16.0 y)	1.1 y (3.4–7.2 y)

Data for kidney transplants received since 2002 at medium or high risk of recurrence of atypical hemolytic uremic syndrome who were not treated with eculizumab (control) and kidney transplants treated with prophylactic eculizumab at the time of transplantation (prophylactic treatment cohort).

TMA, thrombotic microangiopathy.

*P < 0.05,

**P < 0.01,

^***P < 0.001 for difference in proportion of control cohort meeting this criteria compared with prophylactic treatment cohort. There was no difference in median follow-up between groups (P = 0.070).